Beovu Vision Loss Lawsuits
investigating Beovu eye injury cases
Beovu (brolucizumab-dbll), manufactured by Novartis since October 2019, and used to treat wet macular degeneration, is now suspected of causing irreversible eye damage. New data suggests patients who had specific eye problems before getting treated with Beovu may have a higher risk of vision-threatening conditions after treatment. The Swiss drugmaker has released new information based on a recent safety review.
Beovu is used to treat wet macular degeneration, a relatively common chronic eye disorder caused by abnormal blood vessel growth in the eye that leak fluid or blood into the macula, a portion of the retina responsible for central vision. The condition inhibits proteins used to stimulate the growth of new blood vessels in the eye.
If you have had Beovu treatments and suffered from any eye injury or complication, contact The Lyon to review your case. The firm has engaged some of the largest drug companies in the world and settled injury cases on behalf of plaintiffs nationwide.
Wet Macular Degeneration Symptoms
According to Mayo Clinic, wet AMD causes symptoms that can appear suddenly and may worsen rapidly:
- Visual distortions
- Reduced central vision in one or both eyes
- Decreased vividness or color brightness
- A defined blurry or blind spot in your vision
- A general cloudiness in overall vision
Beovu Vision Loss Warning
The American Society of Retinal Specialists has warned about instances of intraocular inflammation, some of which led to vision loss in patients taking Beovu.
According to Novartis’s own clinical review, the highest risk for experiencing retinal vasculitis or retinal vascular occlusion after first treatment was prior intraocular inflammation or vascular occlusion in the year prior to the first Beovu treatment.
The overall complications risk rate was 0.46% for all patients, and the risk increased to 3.97% in people who had the conditions before Beovu treatment. In June 2020, the U.S. Food and Drug Administration (FDA) approved a label update for Beovu® (brolucizumab) to include additional safety information regarding retinal vasculitis and retinal vascular occlusion. The update to the label includes a sub-section discussing retinal vasculitis and retinal vascular occlusion under “Warnings and Precautions.”
The Lyon Firm is also investigating vision loss lawsuits related to Elmiron, which may cause a rare eye disorder called retinal pigmentary maculopathy.
Why are Beovu cases important?
By taking the initiative and filing drug injury lawsuits, plaintiffs can receive proper compensation and hold a corporation accountable for their negligent actions. Consumer safety depends largely on making sure companies operate within the law and within ethical boundaries.
Give Yourself a Voice
Questions about Beovu Lawsuits
Beovu (brolucizumab) is an eye treatment (injection), approved by the FDA for treating age-related macular degeneration (wet AMD).
If you have suffered from vision loss, retinal vasculitis, retinal artery occlusion, intraocular inflammation, or other eye problems after receiving Beovu treatment, you may have a viable case, and may be eligible to recover the following damages:
- Past and future medical expenses
- Past and future pain and suffering
- Loss of Earnings
- Other economic losses
- Punitive damages
- Vision Loss
- Retinal Artery Occlusion
- Retinal Vasculitis
- Intraocular Inflammation
Yes, Beovu is not the only wet AMD drug on the market. Lucentis and Eylea are other eye treatments that have been sold in the US and Europe.
Thus far, no recall has been issued by Novartis or the FDA.
The American Society of Retinal Specialists issued a vision loss warning, stating patients with the highest risk of severe eye injuries after receiving Beovu have prior eye inflammation and/or vascular occlusion.
Pharmaceutical litigation is a complex area of law that combines dense regulation, developing science, and multi-jurisdictional questions of law. Most cases involving claims of drug injury and pharmaceuticals become centralized in the federal multidistrict litigation process. Pharmaceutical litigation involving Beovu injury claims are not in most cases class action lawsuits, but they are very similar.
Due to the volume of cases and number of similar issues, most Beovu cases are handled through Multidistrict Litigation (MDL). The multidistrict litigation procedure is guided by the Judicial Panel for Multidistrict Litigation, where the case is centralized before one federal Judge for the purposes of pre-trial discovery.
The MDL process is appropriate where there are one or more common questions of fact in multiple cases pending in different federal district courts. While there often are parallel state consolidated proceedings, the federal MDL process is generally supported by both Plaintiff and Defendants in these cases.
The MDL process allows for efficiency where there are millions of pages of documents, many expert witnesses across multiple disciplines from epidemiology, pharmacology, toxicology and the specific discipline for the relevant mechanism of injury.
Although 28 USC 1407 does not specify a specific number of cases required before the formation of an MDL is appropriate, the Judicial Panel for Multidistrict Litigation reviews the Motions and conducts a hearing to determine whether consolidation is ripe given the number and location of the pending cases.
Drug Injury Settlements
The Lyon Firm aggressively, professionally, and passionately advocates for injured individuals and families against companies due to a drug to obtain just compensation under the law.
IN RE: VIOXX
Nationwide Consolidation in U.S. District Court, E. Dist. of LA.
This pharmaceutical case involved claims that the blockbuster painkiller was causing heart attacks and strokes in consumers. The FDA ultimately recalled the medication. Merck settled the outstanding Vioxx claims for $4.85 billion following multiple trials in both state and federal courts. Joe Lyon was co-counsel in a number of individual claims that were successfully resolved in the federal MDL. The funds received for Lyon Firm clients helped several elderly clients with additional medical and home health care.
IN RE: TRASYLOL
Nationwide Consolidation in Civil Complex Litigation Center Philadelphia, PA.
A pharmaceutical case involving claims that a popular surgical medication was causing kidney failure and death. The FDA recalled the medication in question, but not before thousands of patients died due to related complications. Bayer resolved certain claims for $60 Million for patients who suffered kidney failure and death as a result of using the drug Trasylol. Joseph Lyon represented a widow from Kentucky whose husband died due to kidney failure following the administration of Trasylol. The recovered funds assisted the surviving family members in resuming farming operations.